Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
Recursion Pharmaceuticals (RXRX -15.53%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage biotech's first-quarter earnings release and business update, and the share price was down by 15% in mid-session trading.
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2025 Results Conference Call May 5, 2025 8:00 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Najat Khan - Chief R&D Officer and Chief Commercial Officer Ben Taylor - Chief Financial Officer Chris Gibson Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our Earnings Call this morning.
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.
Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings
AI is revolutionizing healthcare, with Recursion Pharmaceuticals leveraging AI and vast datasets for drug discovery, making it a compelling investment opportunity. Recursion's integrated drug discovery platform, partnerships with major pharma companies, and significant data resources, position it for growth despite current financial challenges. The FDA's shift towards AI-based models for preclinical drug development could provide Recursion with a strong tailwind, reducing costs and accelerating timelines.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.84, denoting a +1.83% change from the preceding trading day.
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $6.48, denoting a -1.52% change from the preceding trading day.
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
